Product Description
Zeria Co is developing Z-213 as a treatment for Iron Deficiency Anemia. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT02170311)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Zeria Co
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Anemia, Iron-Deficiency|Deficiency Diseases
Phase 1: Deficiency Diseases|Anemia, Iron-Deficiency
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Z213-03 | P3 |
Completed |
Deficiency Diseases|Anemia, Iron-Deficiency |
2017-05-01 |
95% |
| Z213-02 | P3 |
Completed |
Deficiency Diseases|Anemia, Iron-Deficiency |
2017-03-01 |
|
| Z213-01 | P1 |
Completed |
Deficiency Diseases|Anemia, Iron-Deficiency |
2015-02-01 |